Durect Corp (DRRX) 1.00 $DRRX
DURECT to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Jan 29, 3:15PM CST
DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 10 at 8:00 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at https://www.bio.org/events/conferences/bio-ce...rce-center.
DRRX: 1.00 (+0.03)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 39.51 (+0.69), CHTP: 6.52 (-0.03), SUPN: 8.80 (+0.22), ITCI: 24.53 (+2.45), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.00 (+0.03)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ENDP: 84.01 (+1.12), ACT: 285.37 (+3.71), DRRX: 1.00 (+0.03), NVS: 102.20 (-0.17), PTIE: 2.05 (+0.03)
DURECT to Present at the Oppenheimer Healthcare Conference
PR Newswire - Mon Dec 01, 3:30PM CST
DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10 at 3:55 p.m. Eastern Time. The conference is being held at the Crowne Plaza Times Square Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/opco/healthc...127043.cfm.
DRRX: 1.00 (+0.03)
One more safety trial needed for Posidur approval
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:42AM CST
DRRX: 1.00 (+0.03)
DURECT Provides Update on POSIDUR(TM) Program
PR Newswire - Tue Nov 11, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, 2014 regarding the POSIDUR(TM) program. In the February 2014 Complete Response Letter (CRL), FDA indicated that multiple safety trials would be required to support a broad indication. DURECT inquired whether it would be possible to expedite approval by pursuing an initial indication of soft tissue post-surgical analgesia without conducting additional trials. FDA has indicated that in this scenario, it should be acceptable to conduct only one additional soft tissue clinical trial, the size of which is not yet defined, to generate the data required for product approval, including safety data for POSIDUR compared to a non-SABER containing comparator(s) and also product efficacy (to go along with the efficacy already demonstrated in our pivotal hernia trial).
DRRX: 1.00 (+0.03)
DURECT's (DRRX) CEO Jim Brown on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 6:29PM CST
DRRX: 1.00 (+0.03)
Durect posts 3Q loss
Automated Insights - Mon Nov 03, 6:09PM CST
CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Monday reported a loss of $7.1 million, or 6 cents per share, in its third quarter.
DRRX: 1.00 (+0.03)
Durect (DRRX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 3:25PM CST
DRRX: 1.00 (+0.03)
Durect misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:10PM CST
DRRX: 1.00 (+0.03)
DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs
PR Newswire - Mon Nov 03, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014. Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014, compared to total revenues of $3.0 million and net loss of $6.0 million for the three months ended September 30, 2013.
DRRX: 1.00 (+0.03)
Durect reports today after the close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:56AM CST
DRRX: 1.00 (+0.03)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 6.92 (+0.73), PFE: 34.64 (-0.23), SUPN: 8.80 (+0.22), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03), NDRM: 10.76 (+0.22), SHPG: 239.82 (+6.11), ITCI: 24.53 (+2.45)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 7.93 (+0.22), TRNX: 25.32 (+0.12), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBCP: 10.40 (-0.05), PTIE: 2.05 (+0.03), AMDA: 0.65 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.42 (+0.14), FST: 0.34 (-0.02), ZAZA: 2.17 (+0.08), EBR: 1.81 (unch), VTAE: 14.40 (+0.82), XGTI: 0.43 (+0.01), VBIV: 3.01 (+0.01), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBR: 6.98 (+0.44), CBDE: 0.90 (+0.06), OMEX: 0.79 (+0.04), LAYN: 7.93 (+0.22), SRPT: 12.76 (+0.11), CNIT: 3.42 (+0.08), AKBA: 9.32 (+0.51), CTP: 6.53 (+0.13), VPCO: 1.02 (+0.01), PTIE: 2.05 (+0.03)
Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:13AM CDT
GFA: 1.42 (+0.14), PBR.A: 7.13 (+0.48), VNDA: 12.37 (unch), ELP: 11.83 (+0.51), DRRX: 1.00 (+0.03), NBG: 1.61 (+0.18), NQ: 3.95 (-0.03), CEMI: 3.96 (-0.04), VIV: 18.95 (+0.51), PBR: 6.98 (+0.44), BBD: 12.90 (+0.30), NVAX: 8.80 (+0.40), SRPT: 12.76 (+0.11), GOL: 3.85 (+0.01), DGLY: 11.50 (-0.40), ITUB: 12.63 (+0.46), GPRO: 45.27 (-0.02), ERJ: 36.16 (-0.36), EBR: 1.81 (unch), CBD: 32.02 (-0.50), CIG: 4.29 (+0.10), CPL: 13.01 (+0.33), RNA: 18.65 (unch), VALE: 8.05 (+0.32), SBS: 5.41 (+0.21), AEZS: 0.53 (unch), PAY: 35.98 (+1.30), PTIE: 2.05 (+0.03)
DURECT Provides Update on REMOXY® and POSIDUR(TM) Programs
PR Newswire - Mon Oct 27, 7:05AM CDT
DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call
PR Newswire - Fri Oct 24, 3:30PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 1.00 (+0.03)
DURECT to Present at the BIO CEO & Investor Conference
PR Newswire - Thu Jan 29, 3:15PM CST
DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan (Chief Financial Officer) will be presenting at the BIO CEO & Investor Conference on Tuesday, February 10 at 8:00 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City. Investors and analysts that are attending the conference may request a one-on-one meeting through the conference organizers at https://www.bio.org/events/conferences/bio-ce...rce-center.
DRRX: 1.00 (+0.03)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 39.51 (+0.69), CHTP: 6.52 (-0.03), SUPN: 8.80 (+0.22), ITCI: 24.53 (+2.45), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.00 (+0.03)
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 03, 2:41PM CST
MNK: 115.01 (+2.51), JNJ: 99.62 (+1.18), ENDP: 84.01 (+1.12), ACT: 285.37 (+3.71), DRRX: 1.00 (+0.03), NVS: 102.20 (-0.17), PTIE: 2.05 (+0.03)
DURECT to Present at the Oppenheimer Healthcare Conference
PR Newswire - Mon Dec 01, 3:30PM CST
DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10 at 3:55 p.m. Eastern Time. The conference is being held at the Crowne Plaza Times Square Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/opco/healthc...127043.cfm.
DRRX: 1.00 (+0.03)
One more safety trial needed for Posidur approval
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:42AM CST
DRRX: 1.00 (+0.03)
DURECT Provides Update on POSIDUR(TM) Program
PR Newswire - Tue Nov 11, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced that it has received meeting minutes from its face-to-face meeting with the FDA on September 23, 2014 regarding the POSIDUR(TM) program. In the February 2014 Complete Response Letter (CRL), FDA indicated that multiple safety trials would be required to support a broad indication. DURECT inquired whether it would be possible to expedite approval by pursuing an initial indication of soft tissue post-surgical analgesia without conducting additional trials. FDA has indicated that in this scenario, it should be acceptable to conduct only one additional soft tissue clinical trial, the size of which is not yet defined, to generate the data required for product approval, including safety data for POSIDUR compared to a non-SABER containing comparator(s) and also product efficacy (to go along with the efficacy already demonstrated in our pivotal hernia trial).
DRRX: 1.00 (+0.03)
DURECT's (DRRX) CEO Jim Brown on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 6:29PM CST
DRRX: 1.00 (+0.03)
Durect posts 3Q loss
Automated Insights - Mon Nov 03, 6:09PM CST
CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Monday reported a loss of $7.1 million, or 6 cents per share, in its third quarter.
DRRX: 1.00 (+0.03)
Durect (DRRX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 3:25PM CST
DRRX: 1.00 (+0.03)
Durect misses by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:10PM CST
DRRX: 1.00 (+0.03)
DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs
PR Newswire - Mon Nov 03, 3:05PM CST
DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2014. Total revenues were $4.3 million and net loss was $7.1 million for the three months ended September 30, 2014, compared to total revenues of $3.0 million and net loss of $6.0 million for the three months ended September 30, 2013.
DRRX: 1.00 (+0.03)
Durect reports today after the close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:56AM CST
DRRX: 1.00 (+0.03)
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles
M2 - Mon Nov 03, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gdhmp/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - DURECT Corporation - Eli Lilly and Company - Taisho Pharmaceutical Co., Ltd. - NeuroDerm Ltd. - Takeda Pharmaceutical Company Limited - Richter Gedeon Nyrt. - Pfizer Inc. - Purdue Pharma L.P. - Shire Plc - Vernalis plc - Collegium Pharmaceutical, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Arbor Pharmaceuticals, LLC. - Curemark, LLC - Supernus Pharmaceuticals, Inc. - Intra-Cellular Therapies, Inc. - Tris Pharma, Inc. - Neos Therapeutics, Inc. - KemPharm, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Amarantus Bioscience Holdings, Inc. - Mnemosyne Pharmaceuticals, Inc. - Alcobra Ltd - Sunovion Pharmaceuticals Inc. - Signature Therapeutics, Inc - P2D Bioscience For more information visit http://www.researchandmarkets.com/research/3g...on_deficit
ADHD: 6.92 (+0.73), PFE: 34.64 (-0.23), SUPN: 8.80 (+0.22), LLY: 70.56 (+0.03), DRRX: 1.00 (+0.03), NDRM: 10.76 (+0.22), SHPG: 239.82 (+6.11), ITCI: 24.53 (+2.45)
Nasdaq stocks posting largest volume increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LAYN: 7.93 (+0.22), TRNX: 25.32 (+0.12), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBCP: 10.40 (-0.05), PTIE: 2.05 (+0.03), AMDA: 0.65 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:49AM CDT
GFA: 1.42 (+0.14), FST: 0.34 (-0.02), ZAZA: 2.17 (+0.08), EBR: 1.81 (unch), VTAE: 14.40 (+0.82), XGTI: 0.43 (+0.01), VBIV: 3.01 (+0.01), DRRX: 1.00 (+0.03), CEMI: 3.96 (-0.04), PBR: 6.98 (+0.44), CBDE: 0.90 (+0.06), OMEX: 0.79 (+0.04), LAYN: 7.93 (+0.22), SRPT: 12.76 (+0.11), CNIT: 3.42 (+0.08), AKBA: 9.32 (+0.51), CTP: 6.53 (+0.13), VPCO: 1.02 (+0.01), PTIE: 2.05 (+0.03)
Durect and Pain Therapeutics plunge after Pfizer backs out of Remoxy development
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:26AM CDT
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:13AM CDT
GFA: 1.42 (+0.14), PBR.A: 7.13 (+0.48), VNDA: 12.37 (unch), ELP: 11.83 (+0.51), DRRX: 1.00 (+0.03), NBG: 1.61 (+0.18), NQ: 3.95 (-0.03), CEMI: 3.96 (-0.04), VIV: 18.95 (+0.51), PBR: 6.98 (+0.44), BBD: 12.90 (+0.30), NVAX: 8.80 (+0.40), SRPT: 12.76 (+0.11), GOL: 3.85 (+0.01), DGLY: 11.50 (-0.40), ITUB: 12.63 (+0.46), GPRO: 45.27 (-0.02), ERJ: 36.16 (-0.36), EBR: 1.81 (unch), CBD: 32.02 (-0.50), CIG: 4.29 (+0.10), CPL: 13.01 (+0.33), RNA: 18.65 (unch), VALE: 8.05 (+0.32), SBS: 5.41 (+0.21), AEZS: 0.53 (unch), PAY: 35.98 (+1.30), PTIE: 2.05 (+0.03)
DURECT Provides Update on REMOXY® and POSIDUR(TM) Programs
PR Newswire - Mon Oct 27, 7:05AM CDT
DURECT Corporation (Nasdaq: DRRX) reported today that Pfizer Inc. (NYSE: PFE) announced today that it has notified Pain Therapeutics, Inc. (Nasdaq: PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics. As a result, Pain Therapeutics has the rights to develop and commercialize REMOXY on its own or with an alternative licensee. Pain Therapeutics had the rights to develop and commercialize this product candidate under a license from DURECT.
PFE: 34.64 (-0.23), DRRX: 1.00 (+0.03), PTIE: 2.05 (+0.03)
DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call
PR Newswire - Fri Oct 24, 3:30PM CDT
In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 3, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time).
DRRX: 1.00 (+0.03)
